Lupus (SLE) trials in Serbia
8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Belgrade, Kragujevac
- Age
- 5 years to 80 years
- People
- 1,072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - Phase 3Taking peopleA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Where
- Belgrade, Novi Sad
- Age
- 18 years to 75 years
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- Belgrade, Kragujevac, Niška Banja, Novi Sad
- Age
- 16 years and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - Phase 2Taking peopleA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Where
- Belgrade, Zrenjanin
- Age
- 18 years to 74 years
- People
- 405 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00 - Phase 2Taking peopleA Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
- Where
- Belgrade, Niš
- Age
- 5 years to 17 years
- People
- 24 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07630714 · EU 2025-524578-41-00 - Phase 3Enrolling by invitationA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- Where
- Belgrade, Novi Sad
- Age
- 16 years and over
- People
- 760 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00 - Phase 3Enrolling by invitationA Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
- Where
- Belgrade
- Age
- 18 years and over
- People
- 864 worldwide
- Run by
- Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00 - Phase 3Enrolling by invitationLong-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
- Where
- Belgrade, Novi Sad
- Age
- 18 years to 75 years
- People
- 680 worldwide
- Run by
- Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00